Silexion Therapeutics Ltd. (SLXNW)

IL — Healthcare Sector
Peers: VRPX  VINC  DRMA  PIII  FOXO  REVB  ACON  PPBT  AKTX  SYRS 

Automate Your Wheel Strategy on SLXNW

With Tiblio's Option Bot, you can configure your own wheel strategy including SLXNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SLXNW
  • Rev/Share 0.0
  • Book/Share 6.1598
  • PB 0.0054
  • Debt/Equity 0.0695
  • CurrentRatio 3.9681
  • ROIC -1.0142

 

  • MktCap 18512.0
  • FreeCF/Share -9.4786
  • PFCF -0.0017
  • PE -0.004
  • Debt/Assets 0.0418
  • DivYield 0
  • ROE -6.496

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Silexion Therapeutics Ltd. (SLXNW)

  • IPO Date 2024-08-16
  • Website https://silexion.com
  • Industry Biotechnology
  • CEO Ilan Hadar
  • Employees 11
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.